Cargando…
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia
SIRT2 is a member of the NAD+ dependent deacetylases. In this study, the associations between SIRT2 expression and molecular and clinical characteristics of patients with acute myeloid leukemia (AML) were evaluated by data from The Cancer Genome Atlas. SIRT2 was overexpressed in the intermediate- an...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904374/ https://www.ncbi.nlm.nih.gov/pubmed/27291931 http://dx.doi.org/10.1038/srep27694 |
_version_ | 1782437137849778176 |
---|---|
author | Deng, Ailing Ning, Qiaoyang Zhou, Lei Liang, Yaojie |
author_facet | Deng, Ailing Ning, Qiaoyang Zhou, Lei Liang, Yaojie |
author_sort | Deng, Ailing |
collection | PubMed |
description | SIRT2 is a member of the NAD+ dependent deacetylases. In this study, the associations between SIRT2 expression and molecular and clinical characteristics of patients with acute myeloid leukemia (AML) were evaluated by data from The Cancer Genome Atlas. SIRT2 was overexpressed in the intermediate- and poor-risk groups of patients, compared to the favorable-risk group of patients (P = 0.002 and 0.004, respectively). High SIRT2 expression was associated with significantly shorter overall survival (OS; P = 0.0005) and event-free survival (EFS; P = 0.0002) than low SIRT2 expressio in a cohort of 167 patients with AML. Multivariate analyses revealed that high SIRT2 expression was associated with shorter OS (P = 0.031) and EFS (P = 0.020). Gene-expression profiling showed 259 differential expressed genes including CD4, CD14 and IL10. Gene sets like MAPK signaling pathway, VEGF signaling pathway and acute myeloid leukemia were upregulated in SIRT2(high) patients. We also found different methylation patterns in these two groups. OS and EFS of SIRT2(high) patients who did not undergo transplantation were significantly shorter than those of SIRT2(low) patients (P = 0.0120 and P = 0.0107, respectively). Taken together, these findings suggest that high SIRT2 expression is a novel and unfavorable prognostic biomarker for AML risk-stratification. |
format | Online Article Text |
id | pubmed-4904374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49043742016-06-14 SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia Deng, Ailing Ning, Qiaoyang Zhou, Lei Liang, Yaojie Sci Rep Article SIRT2 is a member of the NAD+ dependent deacetylases. In this study, the associations between SIRT2 expression and molecular and clinical characteristics of patients with acute myeloid leukemia (AML) were evaluated by data from The Cancer Genome Atlas. SIRT2 was overexpressed in the intermediate- and poor-risk groups of patients, compared to the favorable-risk group of patients (P = 0.002 and 0.004, respectively). High SIRT2 expression was associated with significantly shorter overall survival (OS; P = 0.0005) and event-free survival (EFS; P = 0.0002) than low SIRT2 expressio in a cohort of 167 patients with AML. Multivariate analyses revealed that high SIRT2 expression was associated with shorter OS (P = 0.031) and EFS (P = 0.020). Gene-expression profiling showed 259 differential expressed genes including CD4, CD14 and IL10. Gene sets like MAPK signaling pathway, VEGF signaling pathway and acute myeloid leukemia were upregulated in SIRT2(high) patients. We also found different methylation patterns in these two groups. OS and EFS of SIRT2(high) patients who did not undergo transplantation were significantly shorter than those of SIRT2(low) patients (P = 0.0120 and P = 0.0107, respectively). Taken together, these findings suggest that high SIRT2 expression is a novel and unfavorable prognostic biomarker for AML risk-stratification. Nature Publishing Group 2016-06-13 /pmc/articles/PMC4904374/ /pubmed/27291931 http://dx.doi.org/10.1038/srep27694 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Deng, Ailing Ning, Qiaoyang Zhou, Lei Liang, Yaojie SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title | SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title_full | SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title_fullStr | SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title_full_unstemmed | SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title_short | SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
title_sort | sirt2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904374/ https://www.ncbi.nlm.nih.gov/pubmed/27291931 http://dx.doi.org/10.1038/srep27694 |
work_keys_str_mv | AT dengailing sirt2isanunfavorableprognosticbiomarkerinpatientswithacutemyeloidleukemia AT ningqiaoyang sirt2isanunfavorableprognosticbiomarkerinpatientswithacutemyeloidleukemia AT zhoulei sirt2isanunfavorableprognosticbiomarkerinpatientswithacutemyeloidleukemia AT liangyaojie sirt2isanunfavorableprognosticbiomarkerinpatientswithacutemyeloidleukemia |